These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10418898)

  • 21. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers.
    Vernacchio L; Bernstein H; Pelton S; Allen C; MacDonald K; Dunn J; Duncan DD; Tsao G; LaPosta V; Eldridge J; Laussucq S; Ambrosino DM; Molrine DC
    Vaccine; 2002 Nov; 20(31-32):3658-67. PubMed ID: 12399193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine.
    Pouliot K; Buglione-Corbett R; Marty-Roix R; Montminy-Paquette S; West K; Wang S; Lu S; Lien E
    Vaccine; 2014 Sep; 32(39):5049-56. PubMed ID: 25045815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.
    Puggioni F; Durham SR; Francis JN
    Allergy; 2005 May; 60(5):678-84. PubMed ID: 15813815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells.
    Thompson BS; Chilton PM; Ward JR; Evans JT; Mitchell TC
    J Leukoc Biol; 2005 Dec; 78(6):1273-80. PubMed ID: 16204643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
    Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
    Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.
    Gorse GJ; Patel GB; Mandava MD; Arbuckle JA; Doyle TM; Belshe RB;
    Vaccine; 2001 Feb; 19(13-14):1806-19. PubMed ID: 11166906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.
    Boyle J; Eastman D; Millar C; Camuglia S; Cox J; Pearse M; Good J; Drane D
    Vaccine; 2007 Mar; 25(14):2541-4. PubMed ID: 17240491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
    Lacaille-Dubois MA
    Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
    Ioannou XP; Gomis SM; Karvonen B; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
    Vaccine; 2002 Nov; 21(1-2):127-37. PubMed ID: 12443671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.
    Dendouga N; Fochesato M; Lockman L; Mossman S; Giannini SL
    Vaccine; 2012 Apr; 30(20):3126-35. PubMed ID: 22326899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity.
    Pacheco SE; Gibbs RA; Ansari-Lari A; Rogers P
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2009-17. PubMed ID: 11153084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a single-shot subunit vaccine for HIV-1.
    Cleland JL; Powell MF; Lim A; Barrón L; Berman PW; Eastman DJ; Nunberg JH; Wrin T; Vennari JC
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S21-6. PubMed ID: 7865303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection.
    Korsholm KS; Petersen RV; Agger EM; Andersen P
    Immunology; 2010 Jan; 129(1):75-86. PubMed ID: 19824919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
    Fuller DH; Haynes JR
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.
    Fraternale A; Paoletti MF; Dominici S; Buondelmonte C; Caputo A; Castaldello A; Tripiciano A; Cafaro A; Palamara AT; Sgarbanti R; Garaci E; Ensoli B; Magnani M
    Vaccine; 2011 Sep; 29(40):6823-9. PubMed ID: 21816192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.